Objectives Thioredoxin-interacting protein (TXNIP) is a regulator of metabolism and inhibitor of the antioxidant thioredoxins. TXNIP binds thioredxins and is therefore also known as Thioredoxin-binding protein 2(TBP-2) or Vitamin D3 upregulated protein 1(VDUP-1). Hypertension, characterised by elevated blood pressure and known as a kind of “cardiovascular syndrome”, is the consequence of metabolic abnormalities to some extent. The close relationship between these processes implicates TXNIP functional expression in the pathogenesis of hypertension. We made attempt to characterise the expression of TXNIP using peripheral blood mononuclear cells (PBMCs) from patients with hypertension.
Methods Total RNA was extracted from the PBMCs of 20 healthy patients with no history of cardiovascular disease and 53 patients with hypertension. The hypertension group was divided into two subgroups based on the risk factor of diabetes: group 1, patients without diabetes; group 2, patients with diabetes. Real-time reverse transcription polymerase chain reaction (RT-PCR) was performed for each group to assess TXNIP mRNA expression.
Results Following logarithmic transformation, theratio peaked at 6.450, displayed a minimum value of 0.000 (average, 2.216 ± 1.509) in the hypertension group. In the control group, the maximum ratio was 6.730, the minimum was 0.870 (average 4.267 ± 1.454). The results indicated that TXNIP expression in PBMCs from patients with hypertension decreased as compared with healthy controls (P < 0.05).
Conclusions Consequently, these results show that TXNIP expression in PBMCs displays a negative correlation with hypertension under treatment. Thus, modulating TXNIP function represents a novel therapeutic approach for future hypertension therapy.